M&A / Deals Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Pharmaceutical TechnologyWhether the deal reaches its full value hinges on US regulatory milestones for Centessa's lead candidate, cleminorexton.M&A / DealsNeuroscienceRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton. M&A / DealsNeuroscienceRead full story Post navigation Previous: Symeres and Ambagon collaborate for colorectal cancer moleculesNext: FDA points to liver injury with Amgen’s Tavneos Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026